Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase NA 1 Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 1 1

Interventions

Cyclophosphamide 143 pembrolizumab 127 Nivolumab 116 Carboplatin 99 Dexamethasone 93 Rituximab 91 Paclitaxel 87 Gemcitabine 85 Lenalidomide 75 Cytarabine 74 Radiotherapy 73 Cisplatin 70 Bevacizumab 64 Etoposide 62 fludarabine phosphate 58 fludarabine 56 Ipilimumab 55 Docetaxel 54 Bortezomib 54 Prednisone 49 Doxorubicin 48 Temozolomide 47 Everolimus 46 Erlotinib Hydrochloride 46 Fluorouracil 44 Azacitidine 44 Capecitabine 43 Calcium Dobesilate 43 Filgrastim 42 Melphalan 41

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Has results × Dosage Forms × Clear all

NCT05309668 2025-12-18

SPRINKLE

AstraZeneca

Phase 1/2 Active not recruiting

36 enrolled 37 charts

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡